(PRRT) is a molecular-based therapy (also known as radioisotope treatment) used to treat certain types of cancer called neuroendocrine malignancies or neuroendocrine tumors (neuroendocrine tumors). Peptide receptor radionuclide therapy (PRRT) is being studied with prostate and pancreatic tumor therapies. In peptide receptor radionuclide therapy (PRRT), a protein (or peptide) called a cell targeting (octreotide) in combination with a small amount of radioactive or radionuclide produces a special type of radiopharmaceutical called radioactive. Peptides. When injected into the patient's blood, the radioactive peptide enters the neuroendocrine tumor cells and attaches to the cancerous lesions to administer a lot of radiation therapy. Concentration (also known as overexpression) in most neuroendocrine tumor cells has a specific type of surface receptor that is distributed on the surface of the cell. This hormone is attached to the body and is called a growth hormone inhibitor. Octreotide is a hormone synthesized in the laboratory that attaches to neuroendocrine tumor growth hormone receptor receptors. Octreotide is one of the most common radionuclides in combination with the therapeutic radionuclides Y-90 and Lu-177 in peptide receptor radionuclide therapy (PRRT).

What is the best cancer for PRRT treatment?

PRRT includes common carcinoid tumors, including pancreatic islet cell carcinoma, small cell lung carcinoma, pheochromocytoma (rare adrenal tumor formation), gastrointestinal-pancreas (gastrointestinal, pancreas) neuroendocrine tumors, Rare thyroid cancer that does not respond to radiation iodine therapy. 

HK HIS leads Singapore Central Hospital, Sunway in Malaysia, PRRT Center in Rotterdam and Cancer Hospital in Peking University.